CHRISTINE HALL: Open Payments
NPI 1205305125 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$575 in 16 payments from 6 companies in 2025. Trend: 2023 $168 · 2024 $168 · 2025 $575
Food & beverage: $575
| Company | Payments | Amount |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | 2 | $235 |
| ABBVIE INC. | 5 | $131 |
| Solventum Corporation | 3 | $81 |
| Paratek Pharmaceuticals, Inc. | 2 | $57 |
| Smith+Nephew, Inc. | 3 | $56 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $16 |
Products named: RECORLEV, GVOKE HYPOPEN, NUZYRA, COLLAGENASE SANTYL, DALVANCE, V.A.C. VERAFLO, AVYCAZ, EMBLAVEO.
Industry payments across MD — which companies pay providers there.
